Home » Stocks » RFL

Rafael Holdings, Inc. (RFL)

Stock Price: $37.84 USD -1.59 (-4.03%)
Updated Apr 19, 2021 11:53 AM EDT - Market open
Market Cap 657.36M
Revenue (ttm) 4.48M
Net Income (ttm) -17.18M
Shares Out 15.88M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $37.84
Previous Close $39.43
Change ($) -1.59
Change (%) -4.03%
Day's Open 39.27
Day's Range 37.33 - 39.59
Day's Volume 16,316
52-Week Range 11.44 - 52.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEWARK, N.J., April 16, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that on April 15, 2021 it made a grant to William Conkling of options to purchase 118,409 shares of Class...

2 days ago - PRNewsWire

Company meets enrollment milestones to support research and development of a new and novel treatment for hard-to-treat cancer Company meets enrollment milestones to support research and development of a...

2 weeks ago - GlobeNewsWire

NEWARK, N.J., March 17, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.50 for the second quarter of its 2021 fiscal year, the three ...

1 month ago - PRNewsWire

NEWARK, N.J., March 11, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that its Board of Directors has recruited Ameet Mallik to become the company's Chief Executive Officer, s...

1 month ago - PRNewsWire

President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wedne...

3 months ago - GlobeNewsWire

CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sa...

3 months ago - GlobeNewsWire

NEWARK, N.J., Dec. 15, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.1 million and a loss per share of $0.09 for the first quarter of its 2021 fiscal year, the three mo...

4 months ago - PRNewsWire

CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that th...

4 months ago - GlobeNewsWire

CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that th...

4 months ago - GlobeNewsWire

CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) --   Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it wi...

4 months ago - GlobeNewsWire

CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will...

4 months ago - GlobeNewsWire

CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that th...

5 months ago - GlobeNewsWire

NEWARK, N.J., Oct. 29, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $4.9 million and a loss per share of $0.66 for the fiscal year ended July 31, 2020. Fourth quarter rev...

5 months ago - PRNewsWire

Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma, in the coming months Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma, i...

5 months ago - GlobeNewsWire

CRANBURY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today its part...

5 months ago - GlobeNewsWire

One of the largest active Phase 3 clinical trials in metastatic pancreatic cancer, completes target enrollment ahead of schedule One of the largest active Phase 3 clinical trials in metastatic pancreat...

8 months ago - GlobeNewsWire

Despite the COVID-19 pandemic, clinical trial for AML continues to actively enroll patients, with established safety precautions Despite the COVID-19 pandemic, clinical trial for AML continues to active...

8 months ago - GlobeNewsWire

NEWARK, N.J., June 9, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per share of $0.14 for the fiscal quarter ended April 30, 2020. Q3 FY 2020 Cons...

10 months ago - PRNewsWire

Cranbury, NJ, May 26, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that th...

10 months ago - GlobeNewsWire

Company advances mission to combat AML, as this research comes on the heels of its Phase 3 trial, actively enrolling globally Company advances mission to combat AML, as this research comes on the heels ...

11 months ago - GlobeNewsWire

Cranbury, NJ, May 05, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it ...

11 months ago - GlobeNewsWire

Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic

11 months ago - GlobeNewsWire

Patient enrollment will begin only once local health officials determine that it is safe, in light of the COVID-19 pandemic Patient enrollment will begin only once local health officials determine that ...

11 months ago - GlobeNewsWire

COVID-19 task force established to support enrolled patients Participating medical centers implemented safety measures and currently enrolling patients COVID-19 task force established to support enrolle...

1 year ago - GlobeNewsWire

Dr. Sehgal joins Rafael Pharmaceuticals to lead the growth of regulatory affairs Dr. Sehgal joins Rafael Pharmaceuticals to lead the growth of regulatory affairs

1 year ago - GlobeNewsWire

Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC) Study authors found that Promitil may be a useful agent in patients with metastatic colorectal...

1 year ago - GlobeNewsWire

Clinical trial further bolsters company’s pipeline in and focus on gastrointestinal cancers Clinical trial further bolsters company’s pipeline in and focus on gastrointestinal cancers

1 year ago - GlobeNewsWire

Clinical trial using devimistat in combination with FOLFIRINOX as first-line treatment has enrolled more than 250 patients ahead of scheduled timeline Clinical trial using devimistat in combination with...

1 year ago - GlobeNewsWire

President and CEO Sanjeev Luther to discuss the status of clinical trials for lead compound CPI-613® (devimistat) and provide update on drug development pipeline President and CEO Sanjeev Luther to disc...

1 year ago - GlobeNewsWire

Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Ar...

1 year ago - GlobeNewsWire

Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Co...

1 year ago - GlobeNewsWire

Cranbury, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the e...

1 year ago - GlobeNewsWire

Cranbury, NJ, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it...

1 year ago - GlobeNewsWire

Dr. Costa Filho joins alongside Timothy Pardee, M.D., Ph.D, who will remain as Co-Chief Medical Officer Dr. Costa Filho joins alongside Timothy Pardee, M.D., Ph.D, who will remain as Co-Chief Medical Of...

1 year ago - GlobeNewsWire

Cranbury, NJ, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the mil...

1 year ago - GlobeNewsWire

Cranbury, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that th...

1 year ago - GlobeNewsWire

Cranbury, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) --   Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...

1 year ago - GlobeNewsWire

CRANBURY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...

1 year ago - GlobeNewsWire

CRANBURY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the ...

1 year ago - GlobeNewsWire

Cranbury, NJ, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that pe...

1 year ago - GlobeNewsWire

About RFL

Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Industry
Biotechnology
Stock Exchange
NYSE
Ticker Symbol
RFL
Full Company Profile

Financial Performance

In 2020, RFL's revenue was $4.91 million, a decrease of -0.43% compared to the previous year's $4.93 million. Losses were -$10.42 million, 121.9% more than in 2019.

Financial Statements